Class II HLA genes account for 10.5% of the genetic variance underlying risk for MS with HLA DRB1*15:01 exerting the strongest effect, although additional alleles, varying across populations, have been inconsistently implicated in MS17–21. The gene discussed is HLA-DRB1; the disease is myeloid sarcoma.